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In spite of the crucial role of heterotrimeric G proteins
as molecular switches transmitting signals from
G protein-coupled receptors, their selective manipu-
lation with small molecule, cell-permeable inhibitors
still remains an unmet challenge. Here, we report
that the small molecule BIM-46187, previously clas-
sified as pan-G protein inhibitor, preferentially si-
lences Gaq signaling in a cellular context-dependent
manner. Investigations into its mode of action reveal
that BIM traps Gaq in the empty pocket conformation
by permitting GDP exit but interdicting GTP entry, a
molecular mechanism not yet assigned to any other
small molecule Ga inhibitor to date. Our data show
that Ga proteins may be ‘‘frozen’’ pharmacologically
in an intermediate conformation along their acti-
vation pathway and propose a pharmacological
strategy to specifically silence Ga subclasses with
cell-permeable inhibitors.
INTRODUCTION
Heterotrimeric abg guanine-nucleotide-binding proteins (G
proteins) are molecular switches that relay signals from activated
G protein-coupled receptors (GPCRs) to (intra)-cellular effector
systems such as ion channels or enzymes that, in turn, control890 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Lproduction, release, or degradation of second messengers
(Wall et al., 1998; Neves et al., 2002; Milligan and Kostenis,
2006; Johnston and Siderovski, 2007; Oldham and Hamm,
2008). These G proteins function by adopting two principal
conformational states: an ‘‘off state’’ in which guanosine diphos-
phate (GDP)-bound Ga is in complex with the Gbg heterodimer,
and an ‘‘on state’’ in which guanosine triphosphate (GTP)-bound
Ga is liberated from its Gbg binding partner. Ligand-activated
GPCRs act as guanine nucleotide exchange factors (GEFs) for
G proteins that stimulate exchange of GDP for GTP on the Ga
subunit (Wall et al., 1998; Johnston and Siderovski, 2007; Old-
ham and Hamm, 2008; Kimple et al., 2011). Crystal structures
have been resolved for both GDP-bound inactive and GTP-
bound active conformations and have shed light on the discrete
differences of these nucleotide-dependent conformational
states (Oldham and Hamm, 2008). Consequently, efforts have
been undertaken to develop nucleotide-state-selective inhibitors
for both inactive GDP-bound heterotrimers and active GTP-
bound Ga or Gbg dimers (Johnston et al., 2008; Bonacci et al.,
2006). Despite enormous advances in understanding structure
and function of Ga proteins at a mechanistic level since their
discovery, very few small molecule Ga subunit inhibitors with ac-
tivity in whole cells have been reported to date (Smrcka, 2013). In
fact, of the four families of Ga proteins (Gai/o, Gas, Gaq/11, and
Ga12/13) only Gai/o proteins can be specifically inhibited with
pertussis toxin (PTX), which has served as an invaluable probe
toanalyzeGPCRsignalingmechanismsandGai-mediated cell re-
sponses (Mangmool and Kurose, 2011; Saulie`re et al., 2012;
Ashkenazi et al., 1989; Wong et al., 1991; Itoh et al., 2003). PTX,
however, cannot be considered a small molecule but representstd All rights reserved
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Trapping Gaq in the Empty Pocket Conformationa typical A-B toxin using its A protomer to ADP-ribosylate Gai/o
protein family members and thereby uncouple receptors from
their cognate G proteins (Mangmool and Kurose, 2011; West
et al., 1985). YM-254890, a cyclic depsipeptide isolated from
the fermentation broth of Chromobacterium sp. QS3666, has
recently been shown to specifically silence function of Gaq/11 pro-
teins, includingGa14 (Takasaki et al., 2004;Nishimura et al., 2010).
YM-254890 is the only inhibitor for which high-resolution
structural information is available to provide the framework for
understanding its mechanism of action at the molecular level.
A major shortcoming of YM-254890 is that it is not commercially
available and, therefore, is only accessible for very few research
laboratories worldwide.
In spite of their diverse structures, all inhibitors of Ga function
apparently share a common mechanism of action, i.e., bind to
Ga subunits to prevent receptor-mediated or intrinsic nucleotide
exchange (Smrcka, 2013). This mechanism of action also was
proposed for two small molecules, BIM-46174 and BIM-46187,
suggested as experimental anticancer drugs (Pre´vost et al.,
2006; Ayoub et al., 2009). BIM-46174 was identified in a differen-
tial screening approach as a molecule that inhibits cyclic AMP
(cAMP) production in MCF7 cancer cells that were pretreated
with the irreversible Gas activator choleratoxin but not in those
pretreated with the direct adenylyl cyclase activator forskolin
(Pre´vost et al., 2006). Such a screening strategy allows identifi-
cation of compounds that target Gas proteins but not Gas-sensi-
tive receptors or adenylyl cyclases. Additional mechanistic
investigations revealed that both BIM molecules display an
intriguing pharmacological phenotype in that they do not only
target heterotrimeric G proteins of the Gas family but also target
Gaq/11, Gai/o, andGa12/13 proteins, a feature referred to as pan-G
protein inhibition (Pre´vost et al., 2006; Ayoub et al., 2009).
An initial goal of the present studywas to take advantage of the
pan-G protein inhibitory nature of BIM-46187 to specifically
investigate G protein-independent signaling. However, we found
that BIM-46187 does not abolish signaling of all Ga subfamilies
equally but instead acts in a cellular context-dependent manner,
ranging from pan-G protein inhibition to selective Gaq silencing.
We identified mammalian human embryonic kidney 293
(HEK293) and Chinese hamster ovary (CHO) cells, two cell lines
frequently used to examine signaling of recombinant or endoge-
nous GPCRs, as hosts in which BIM-46187 specifically silences
Gaq over Gas, Gai, and Ga13 proteins. Based on the Gaq-specific
inhibition, we investigated the molecular mechanism underlying
BIM-46187 action. Our results are consistent with the idea that
BIM-46187 targets Ga proteins and show that it interferes with
agonist function, but not agonist binding to Gaq-sensitive
GPCRs, by exhibiting amechanism not yet assigned to any other
small molecule Ga inhibitor to date.
RESULTS
BIM-46174 and themore stable derivative BIM-46187 (Figure 1A,
also referred to as BIM-monomer and BIM-dimer, respectively)
are two small molecules that interdict signaling of GPCRs by
direct binding to and inhibition of a subunits of heterotrimeric
G proteins (Pre´vost et al., 2006; Ayoub et al., 2009). Both mole-
cules are thought to inhibit all Ga subfamilies equally and there-
fore serve to silence receptor signaling in complex pathologiesChemistry & Biology 21,that involve multiple GPCRs (Smrcka, 2013; Pre´vost et al.,
2006). We wanted to take advantage of the pan-G protein inhib-
itors to specifically dissect G-protein-dependent versus G-pro-
tein-independent signaling events mediated by cell surface
GPCRs. We hypothesized that the free thiol group-containing
monomeric BIM should be intrinsically sensitive to oxidation;
therefore, we initially investigated stability in aqueous solution
(D2O) over time by nuclear magnetic resonance (NMR) spectros-
copy (Figure 1B). NMR spectra are clearly indicative of BIM-
monomer oxidation in a time-dependent manner: After 48 hr,
BIM-monomer is virtually undetectable (Figure 1C). Since the
integration area of the signals correlates with the concentration
of BIM-monomer, we were able to deduce a half-life of 11.4 hr
for this first-order reaction (Figure 1D and Table S1 available
online). We reasoned that oxidation of BIM-monomer should
depend on the presence of reducing agents and therefore
examined stability by NMR in D2O containing reactive thiols
(L-cysteine, glutathione [GSH]), and mercaptoethanol. Indeed,
under these conditions, quantitative formation of covalent
complexes with selected thiols was observed: BIM-cysteine,
BIM-mercaptoethanol, and BIM-dimer (Figure S1). Additionally,
we investigated the stability of both BIM-monomer and -dimer
during cellular assays by analyzing the cell culture supernatant
with liquid chromatography-mass spectrometry. We identified
BIM-cysteine, BIM-mercaptoethanol, BIM-dimer, or BIM-mono-
mer, respectively, after 24 hr at 37C (Figure S2). These data
suggest that (1) assessment of biological activity of BIM-
monomer should take into account that extracellular BIM-mono-
mer might be entirely converted to BIM-dimer during the assay
period, and (2) that both BIM molecules are prone to formation
of redox-reversible adducts when thiol-containing components
are present. This notion might be particularly relevant when anti-
proliferative activity of BIM is assessed, because such assays
typically range from many hours to days.
Despite the short duration of assays that assess GPCR activity
by quantifying intracellular secondmessengers and the absence
of reducing agents in these assays, we chose the chemically
more stable BIM-dimer for further studies. In agreement with
the inability of BIM to affect cAMP production in the breast can-
cer MCF7 and COS7 cell background upon stimulation with the
direct adenylyl cyclase mimetic forskolin (Pre´vost et al., 2006;
Ayoub et al., 2009), it did not blunt cAMP synthesis in forsko-
lin-stimulated HEK293 cells (Figure 2A). It is surprising, however,
that BIM also was largely ineffective when cAMP production was
triggered with prostaglandin E1 (PGE1), a bona fide stimulus of
the Gas-linked E prostanoid EP2 and EP4 receptors that are
endogenously expressed in this cell system (Figure 2B). Proper
functionality of our cAMP assay was ascertained by preincuba-
tion of cells in the presence of an EP2/EP4 antagonist, which
completely blunted PGE1-mediated cAMP synthesis (Figure S3).
Lack of BIM inhibition of Gas-coupled receptor signaling is not
due to BIM decomposition during the assay period, because
BIM significantly dampened EP2/EP4 receptor signaling in a
COS7 cell background (Figure 2C). We therefore reasoned that
BIM interferes with G protein signaling in a cell-type-specific
manner. Such a pharmacological phenotype would be of rele-
vance for an anticancer agent, particularly if it is applied under
the assumption that the entire set of G protein pathways is
silenced simultaneously in any cell type.890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 891
Figure 1. Structures of BIM-Monomer and BIM-Dimer and Stability in Aqueous Solution, D2O, as Determined by NMR Spectroscopy
(A) Chemical structures of the BIM-monomer and the BIM-dimer.
(B) 1HNMRof the BIM-monomer at t = 0 hr. The signals at d = 7.4–7.8 ppmbelong to the protons of the aromaticmoiety and the imidazole ring. The signal at d = 6.0
ppm corresponds to the proton in position 2 and the area from d = 4.0 to 5.0 ppm comprises the protons of position 12, 13 and 15 partially overlayed by the
residual solvent (DOH) signal. At about d = 3 ppm, the diastereotopic methylene protons next to the thiol group resonate (position 16), followed by the DMSO
signal and the high-field shifted protons of the cyclohexylmethyl group.
(C) Oxidation of the BIM-monomer over time. The oxidation process can be observed using the protons in position 2 and 16. At t = 0 hr, only the proton signals of
the monomer were observed. Within 48 hr, the integration areas of the signals of the monomer protons decrease, while the dimer signals increase until 100%
dimer was observed at t = 48 hr. h, hours. R-SH denotes BIM-monomer, and R-S-S-R denotes BIM-dimer.
(D) A diagram of the natural logarithm of the concentration (ln c) of BIM-monomer versus time. Since the integration area of the signals in (C) correlates with the
concentration of the BIM-monomer, a half-life of 11.4 hr is calculated for this first-order reaction.
See also Figures S1 and S2 and Table S1.
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Trapping Gaq in the Empty Pocket ConformationTo explore the consequences of BIM exposure for function-
ality of the remaining G protein pathways, HEK293 cells were
treated with a set of different stimuli for Gai-, Gaq-, and Ga13-
linked receptors that are natively or were exogenously ex-
pressed in this cell system. It is interesting that preincubation
of cells with BIM completely abolished signaling of Gaq-sensitive
receptors (Figures 3A–3C) but hardly affected signaling of those
that are functionally coupled to Gai proteins (Figures 3D–3F).
Even when cells were preincubated with 100 mM of BIM—the
highest applicable concentration—robust Gai activation was still
detected. A similar lack of BIM inhibition was observed when
GPCR engagement of Ga13 signaling was recorded using
lysophosphatidylinositol and its target receptor GPR55 in
bioluminescence resonance energy transfer (BRET) assays.892 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier LWe recorded a substantial agonist-promoted decrease in
BRET in cells coexpressing GPR55 along with the energy donor
Ga13-106RLuc8, the energy acceptor Gg2-GFP
10, and unlabeled
Gb1. This BRET decrease reflects the separation of the Ga-heli-
cal domain from the N terminus of Gg thereby creating the route
for GDP exit and GTP entry (Gale´s et al., 2006; Saulie`re et al.,
2012). Pretreatment of transfected cells with BIM did not alter
GPR55-Ga13 activation (Figure 3G) but significantly blunted acti-
vation-dependent rearrangement of the Gaq-b1g2 heterotrimer
triggered with carbachol via muscarinic M3 receptors (Fig-
ure 3H). These results suggest that the BRET partners used
are suitable for examining inhibition of G protein signaling by
BIM and that BIM is competent to interdict Gaq but not Ga13
signaling.td All rights reserved
Figure 2. Effects of BIM on Cellular cAMP Levels in an HEK293 and
COS7 Cell Background
(A) Increasing concentrations of BIM do not lower forskolin-mediated cAMP
production in HEK293 cells.
(B) BIM slightly diminishes cAMP signaling of the Gas-sensitive EP2/EP4 re-
ceptors in HEK293 cells. Negative logarithm of EC50 (pEC50) for PGE1 (without
[w/o] BIM) = 8.91 ± 0.07; pEC50 for PGE1 (100 mM BIM) = 8.29 ± 0.06.
(C) BIM largely suppresses prostaglandin E1-mediated cAMP production in
COS7 cells. Data shown in (A) through (C) are mean values ± SEM of three to
ten independent experiments, each performed in triplicate.
See also Figure S3.
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Chemistry & Biology 21,So far, BIM has been applied to a number of different cancer
cell lines, such as breast cancer MCF7 and human colorectal
cancer HCT8/S11 and HT29, among many others (Ayoub
et al., 2009; Pre´vost et al., 2006). Nonetheless, its utility to silence
all G protein signaling pathways in immortalized cell lines that are
frequently used for recombinant expression such as HEK293 or
CHO is undefined. So far, only COS7 cells have been used as an
immortalized host in elegant studies to examine the mechanism
of BIM action in great detail (Ayoub et al., 2009). We therefore
investigated the influence of BIM on second messenger path-
ways using CHO cells as an expression system. Again, BIM
did not exert pan-G protein inhibitory activity but rather targeted
Gaq proteins as evidenced by the clear preference to interdict
signaling of the Gaq-sensitive muscarinic M1 receptor over
Gas-linked prostanoid and Gai-linked serotonin receptors (Fig-
ures 4A–4C). A similar preference for inhibition of Gaq-signaling
was observed when monomeric BIM was applied in analogous
second messenger assays, both in CHO (Figures 4D–4F) and
HEK cell backgrounds (Figures 4G–4I). From these data, we infer
that (1) cellular context-dependent inhibition of Gaq signaling is
not related to the inability of the cells to convert dimeric BIM
into its reduced counterpart, and hence to different reductive ca-
pacities of cells; and (2) dimeric BIM is superior to monomeric
BIM for silencing of Gaq signaling, at least in the CHO and HEK
cell backgrounds.
We next addressed whether the absence of pan-G protein
inhibition may be related to the export of BIM via multidrug
transporters. If BIMwas a substrate for active outward transport,
inhibition of BIM efflux by coadministration of a transport inhibi-
tor should improve its capacity to interdict Gaq signaling. To test
this assumption, we pretreated HEK cells, which endogenously
express multidrug transporters, with MK571 or elacridar to block
efflux protein activity. MK571 inhibits MRP1 and MRP2, two
transporters that export hydrophilic molecules and GSH conju-
gates (Wortelboer et al., 2003; Leyers et al., 2008). Elacridar in-
hibits P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP), the former preferring hydrophobic and the latter trans-
porting rather diverse and nonconjugated compounds (Ahmed-
Belkacem et al., 2005). None of the applied inhibitors rendered
Gaq signaling more sensitive toward BIM inhibition (Figure S4).
Thus, we conclude that export of BIM via multidrug transporters
does not account for cell-type-specific differences in G protein
inhibition profiles.
It is interesting to note that BIM displays antiproliferative ef-
fects in HEK cells (Pre´vost et al., 2006) yet only silences Gaq
signaling in this cellular background. Furthermore, the effective
concentration of BIM to inhibit cellular proliferation is much lower
as compared with the concentration required to achieve full
silencing of Gaq signaling (compare Pre´vost et al., 2006 with Fig-
ure 3). Such data imply that inhibition of Gaq signaling may be
sufficient for blockade of cellular proliferation or that the antipro-
liferative effects of BIM are unrelated to pan-G protein inhibition.
To explore a mechanistic link between G protein inhibition and
abrogation of cell growth, we chose to directly compare these
parameters in the patient-derived human skin cancer cell line
MZ7. BIM exhibited concentration-dependent inhibition of cell
growth in MZ7 cells as evidenced by crystal violet staining
and determination of cell viability in parallel treatment groups
(Figure 5A). A similar reduction of cell growth was obtained on890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 893
Figure 3. BIM Interdicts Gaq Signaling but Not Gai or Ga13 Signaling in HEK293 Cells
(A–C) BIM (100 mM) silences Gaq activation induced by stimulation of three Gaq-sensitive receptors (muscarinic M3, P2Y, and FFA2) with their cognate agonists
carbachol, ATP, and propionic acid, respectively. w/o, without.
(D–F) BIM (100 mM) hardly affects productive Gai interaction of FFA2 and FFA3, as well as OXE-R.
(G and H) BIM does not block molecular rearrangement of activated Ga13 (G) but efficiently dampens activation of the Gaq-BRET biosensor (H). Opening of the
nucleotide binding pocket is detected as BRET decrease after receptor activation in HEK293 cells transfected to express Ga13-106RLuc8 + Gg2-GFP
10 +
unlabeled Gb1 (G) or Gaq-97RLuc8 + Gg2-GFP
10 + unlabeled Gb1 (H). ***p < 0.001; n.s., not significant.
The means ± SEM in (A) through (F) or + SEM in (G) and (H) of three to six independent experiments, each conducted in triplicate, are shown.
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Trapping Gaq in the Empty Pocket Conformationtreatment with the DNA-replication inhibitor aphidicolin, which
inhibits cell cycle progression at the G1/S phase (Figure 5A).
However, aphidicolin-arrested cells resumed cell growth on in-
hibitor removal as opposed to BIM-treated cells, indicating that
BIM likely induces cell death. It is interesting that inhibition of
cell growth by BIM was maximal at 10 mM, yet an even greater
10-fold increase of BIM concentration was required to dampen
cellular signaling via Gai, Gas, and Gaq pathways (Figures 5B–
5D). BIM inhibition of second messenger pathways appears to894 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Loccur specifically at the level of the G proteins, even at these
high concentrations, because prior addition of 100 mM BIM
completely blocked endothelin-1, but not thapsigargin-induced
Ca2+ mobilization (Figure 5B), and because BIM did not lower
cAMP production triggered with forskolin (Figure S5) but
completely prevented cAMP formation in response to adreno-
corticotropic hormone (ACTH), a stimulus for the Gas-sensitive
melanocortin 1 (MC1) receptor (Figure 5C). Together, these
data indicate that BIM does indeed silence all three secondtd All rights reserved
Figure 4. Monomeric and Dimeric BIM Preferentially Silence Gaq Signaling in a CHO and HEK293 Cell Background
(A–C) Dimeric BIM almost completely blunts Gaq signaling over Gas and Gai signaling in CHO cells transfected to express the muscarinic M1 receptor (A) or
endogenously expressing Gas-linked EP2/EP4 receptors (B) and the Gai-sensitive serotonin 5-HT receptors (C).
(D–F) Monomeric BIM resembles dimeric BIM in its ability to preferentially silence Gaq signaling of the muscarinic M1 receptor (D) over Gas signaling of EP2/EP4
receptors (E) or Gai signaling of serotonin 5-HT receptors (F) in a CHO cell background yet displays reduced potency and efficacy.
(G–I) Monomeric BIM partially diminishes Gaq activation of the muscarinic M3 receptor in HEK293 cells (G) but does not dampen signaling mediated via
Gas-sensitive EP2/EP4 receptors (H) or Gai-sensitive CRTH2 receptors (I). Means ± SEM of at least three experiments, each conducted in triplicate, are shown.
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Trapping Gaq in the Empty Pocket Conformationmessenger pathways in the cancer MZ7 cell background but at
concentrations clearly exceeding those required to inhibit cell
growth. This discrepancy may be explained by (1) short (second
messenger assays) versus long (cell growth assays) BIM prein-
cubation times; (2) cumulative/cooperative effects of BIM in
cell growth assays, where multiple signaling pathways are
silenced simultaneously; and/or (3) abrogation of ligand-stimu-
lated signaling (second messenger assays) versus endogenous
receptor signaling (cell growth assays).
Context-dependent pharmacology of GPCR ligands is a well-
known phenomenon that is widely appreciated. Often, cell-type-
specific differences in the relative amount or stoichiometry of
signaling components may account for functionally differentChemistry & Biology 21,effects of ligands across cell lines (Kenakin and Christopoulos,
2013). We therefore investigated whether the extent of BIM inhi-
bition may be related to the level of expression of its protein
target. To this end, HEK293 cells were enriched with increasing
amounts of Gaq proteins using a gene dosing approach (Figures
6A and 6B), and sensitivity of Gaq proteins toward BIM inhibition
was examined in assays monitoring inositol monophosphate
(IP1) production upon stimulation of endogenous muscarinic
M3 receptors with carbachol. Indeed, a clear correlation be-
tween BIM inhibition and Gaq expression could be detected:
BIM inhibition gradually declined when cellular abundance of
Gaq proteins was raised (Figure 6C). These data imply a link be-
tween the expression level of BIM target proteins and the extent890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 895
Figure 5. BIM Inhibits Cell Growth and Second Messenger Production in the Patient-Derived MZ7 Cancer Cell Background
(A) MZ7 cancer cells were exposed to the indicated concentrations of BIM or the cell cycle inhibitor aphidicolin for 72 hr and cell proliferation was assessed by
crystal violet staining (green bars). In parallel treatment groups cell viability wasmeasured using the XTT-based cell viability kit (orange bars), means + SEM, n = 3.
(B) In (i), untreated MZ7 cells respond to both the Gaq–stimulus endothelin-1 (ET-1) and thapsigargin (Thaps). (ii) BIM completely blunts Ca
2+ mobilization
triggeredwith ET-1 but does not impair thapsigargin-induced release of Ca2+ from the endoplasmic reticulum. (iii) Quantification of Ca2+ traces in the absence and
presence of BIM in single cells. Data in (i) and (ii) show representative traces; data in (iii) are means + SEM of n = 159 cells. sec, seconds. ***p < 0.001.
(C) At a concentration of 100 mM, BIM silences Gas-mediated cAMP production induced via ACTH and its cognate Gas-linked MC1 receptor.
(D) BIM diminishes Gai coupling of endogenous ET-1 receptors. Data shown in (C) and (D) are means ± SEM of three to ten independent experiments, each
conducted in triplicate.
See also Figure S5.
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Trapping Gaq in the Empty Pocket Conformationof BIM inhibition. We reasoned that the disparate G protein inhi-
bition profiles observed in MZ7 versus HEK293 cells might also
be related to cellular Ga abundance and quantified expression
of Gaq, Gas, and Gai proteins by immunoblotting in both cell896 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Llines. Figures 6D–6F reveal equal expression of Gaq but sig-
nificantly lower abundance of Gas in theMZ7 background. These
data lend further support to the notion that Ga subunit ex-
pression and BIM inhibition might be mechanistically linked.td All rights reserved
Figure 6. Mechanistic Link between Sensitivity toward BIM Inhibition and Cellular Abundance of BIM Target Proteins
(A) Immunoblot detection of HEK293 lysates prepared after transfection with the indicated amounts of Gaq plasmid complementary DNA harboring an
internal HA-epitope tag. Membranes were reprobed for tubulin to ensure equal sample loading and transfer. Shown is one representative of four independent
experiments.
(B) Densitometric analysis of the immunoblot experiments depicted in (A). Means ± SEM of four individual experiments are shown.
(C) Enrichment of HEK293 cells with the indicated amounts of Gaq proteins is inversely related to BIM inhibition of Gaq signaling (means ± SEM, n = 4).
(D) Immunoblot detection of lysates prepared from native HEK293 and MZ7 cells. Membranes were initially probed for Gaq, Gai, and Gas proteins and then
reprobed for tubulin to ensure equal sample loading and transfer. Shown is one representative of three independent experiments.
(E and F) Densitometric analysis of the immunoblot experiments depicted in (D); means + SEM, n = 3.
Chemistry & Biology
Trapping Gaq in the Empty Pocket ConformationHowever, enhanced abundance of Gai proteins in MZ7 cells is
incongruent with our hypothesis. Together, these data may
help explain the absence of pan-G protein inhibition across
diverse cell lines yet also indicate that variation in Ga expression
does not exclusively account for cell-type-dependent pharma-
cology of BIM. Clearly, the mechanistic basis underlying cellular
context-dependent inhibition must be ascribed to additional
reasonswhy this apparent paradox exists betweenGaq selective
inhibition in some cells and pan-G protein inhibition in others.
We were intrigued by the finding that BIM might serve to spe-
cifically abrogate Gaq signaling in defined cellular environments
and wanted to ascertain that perturbation of Gaq-sensitive re-
ceptor function is not due to disruption of agonist binding. We
chose the carbachol-ligated muscarinic M1 receptor as a model
system using radioligand competition assays. Our binding as-
says in whole CHO-M1 cells clearly revealed that BIM did notChemistry & Biology 21,impair but rather enhanced carbachol displacement of the
radio-antagonist [3H]N-methylscopolamine ([3H]NMS) from M1
receptors (Figure 7A). Hence, inhibition of Gaq signaling by
BIM in CHO-M1 cells is due to BIM interference with agonist
function but not agonist binding.
BIM has been reported to completely prevent G protein
activation in [35S]GTPgS binding assays, regardless of whether
activation is achieved with a ligand-occupied GPCR, the direct
G protein activators mastoparan or AlF4
, or the Gai mimetic
FUB132 (Pre´vost et al., 2006; Ayoub et al., 2009). While all of
these studies support a direct action of BIM on the Ga protein
itself, it has not yet been clarified whether BIM impairs GDP
exit or GTP entry. To discriminate between these possibilities,
we performed radioligand binding assays on membranes iso-
lated from CHO-M1 cells using the radio-antagonist [3H]NMS.
Initial homologous competition experiments indicated that BIM890–902, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 897
Figure 7. Effect of BIMonCarbachol Recognition of theM1Muscarinic Receptor in RadioligandCompetition Binding Assays and on [3H]GDP
Dissociation from Purified Gaq
(A) BIM (100 mM) enhances carbachol affinity to muscarinic M1 receptors labeled with the radio-antagonist [3H]NMS in whole CHO-M1 cells: pKI(control) = 3.61 ±
0.08, (n = 6); pKI(BIM) = 4.09 ± 0.09, n = 3, p < 0.05. w/o, without.
(B) In membrane preparations from CHO-M1 cells, carbachol competes for [3H]NMS sites with high and low affinity. In the presence of 1 mM GTP, 51% of the
high-affinity sites were converted to low-affinity sites.
(C) BIM (100 mM) does not impair formation of high-affinity agonist complexes in CHO-M1 membranes.
(D) BIM (100 mM) does not impair [3H]GDPdissociation frompurified recombinant Gaq. [
3H]GDPwas preloaded onGaq for 18 hr before dissociation was visualized
in the presence of 750 mM (NH4)2SO4.
(E) BIM counteracts the effect of GTP on high-affinity agonist binding in membrane preparations from CHO-M1 cells. In the absence of GTP, 20% of receptors
resumed the high-affinity state that was reversed entirely in the presence of GTP, the effect of whichwas counteracted by BIM. Data in (A) through (E) aremeans ±
SEM of three to four independent experiments, each conducted at least in duplicate.
(legend continued on next page)
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(Figure S6). If BIM acted as guanine-nucleotide dissociation in-
hibitor (GDI), i.e., precluded GDP exit from the nucleotide binding
pocket, it would be evident as inhibition of high-affinity agonist
binding, a conformational receptor state that is stabilized by the
nucleotide-free, empty-pocket G protein (De Lean et al., 1980;
Oldham and Hamm, 2008; Rodbell et al., 1971). Note that high-
affinity ternary complexes can only be visualized when guanine
nucleotides are absent but are short-lived intermediates in intact
cells where guanine nucleotides are abundant (Rodbell et al.,
1971; Oldham and Hamm, 2008; Seifert et al., 1999; De Lean
et al., 1980). We also detected high affinity-binding of carbachol
to G-protein-coupled and low-affinity binding to G-protein-
uncoupled M1 receptors in [3H]NMS competition binding assays
(Figure 7B and Table S2). GTP (1 mM) almost completely con-
verted the high-affinity sites to a low-affinity population because,
under these conditions, GDP is rapidly exchanged for GTP and
the short-lived empty pocket conformation is no longer detect-
able (Figure 7B and Table S2). In contrast, high-affinity agonist
binding was indistinguishable in the absence and presence of
BIM, suggesting that it does not uncouple receptors from their
cognate G proteins (Figure 7C and Table S2). Thus, despite the
presence of BIM, stable active-state complexes do form, indi-
cating that BIM uncouples high-affinity agonist binding from
agonist function. This mode of action can only be rationalized if
BIM permitted GDP exit but precluded GTP entry. To further
substantiate the proposed mechanism of action, we measured
[3H]GDP dissociation from purified recombinant Gaq. Since
Gaq-bound GDP dissociates very slowly (Chidiac et al., 1999),
we took advantage of (NH4)2SO4 to accelerate and, therefore,
visualize its dissociation. GDP dissociation in the presence of
750mM (NH4)2SO4was completewithin 120min but, notably, un-
affected by the presence of BIM (Figure 7D). These data strongly
suggest that BIM does not act as a GDI but permits egress of
GDP from the nucleotide binding pocket. BIM, however, does
counteract the effect of GTP on high-affinity agonist binding (Fig-
ure 7E). Therefore, our results are entirely consistentwith the view
that BIM inhibits Gaq function by permittingGDPexit but preclud-
ing GTP entry, i.e., ‘‘freezes’’ Gaq in the empty pocket conforma-
tional intermediate along the activation pathway.
To rationalize this mode of inhibitor action, we conducted
docking experiments and all-atom molecular dynamics (MD)
simulations to assess the effect of BIM on motions required for
nucleotide exchange. Given the absence of mutagenic mapping
or structural data, two scenarios were taken into consideration.
The first scenario was covalent attachment to cysteine residues
that are conserved among all Ga proteins but are not part of the
Ga/Gbg interface (C144 and C330 within Gaq). This assumption
is based on the notion that BIM, in principle, inhibits all Ga sub-
families but does not impair formation of Ga-Gbg heterotrimers
in vitro (Ayoub et al., 2009). The second scenario was noncova-
lent binding to an epitopewithin Ga, as determined through inde-
pendent molecular docking experiments. Docking results reveal(F and G) Root-mean-square-fluctuations (RMSF) as a function of their residue
BIM covalently bound to GDP-Gaq (red trace). (G) Simulation of GDP-Gaq (black t
BIM-dimer binding site encompassing residues 292–311 (aG-a4 loop and a4 he
(H) BIM-dimer complex conformation I after 10 ns of MD simulation.
See also Figures S6–S8 and Table S2.
Chemistry & Biology 21,high binding energies and a large overlap in the binding sites for
BIM-monomer and -dimer, respectively, at least for the best
scoring cluster conformations (Figure S7 and Table S3).
We then subjected the individual Ga-BIM complexes to all-
atom MD simulations. We calculated average protein structures
and used fluctuations of Ca residues relative to the average
structure as a measure of dynamic motion, which is often linked
to intrinsic domain motion (Jones et al., 2012). As shown in Fig-
ure 7F, fluctuations in GDP-Gaq (indicated by black trace) are
greatest in the three switch regions of the Ras-like domain and
in the aB-aC loop of the helical domain (please note that the
energy donor RLuc of our Gaq BRET sensor is inserted into the
aB-aC loop). When BIM is covalently bound to Cys330 within
Gaq (Figure 7F, red trace), the magnitude of local fluctuations
in switch regions II and III and in the aB-aC loop is clearly dimin-
ished. This reduction in local mobility aligns well with the
impaired helical domain motion that is detected in our BRET ex-
periments (compare with Figure 3H). In contrast, when BIM is
linked to Cys144, only switch region II and the aB-aC loop
display reduced mobility (Figure S8, blue trace). It is intriguing
that we observed even higher reduction in local fluctuations,
particularly in switch region III for the best scoring complex
conformation of BIM-dimer (Figure 7G, magenta trace, and Fig-
ure 7H). No changes in the local fluctuations were recorded for
the other complex conformations analyzed with all-atom MD
simulations (Figures S8B–S8D). Together, we propose three po-
tential binding sites for BIM. All of these sites are compatible with
the notion that BIM impairs intradomain motion within Ga by
compromising local mobility, most likely the conformational
changes required for GTP binding in the switch regions, and
additionally, the large motion of the helical domain away from
the Ras-like domain, a prerequisite for GDP/GTP exchange.
DISCUSSION
Great therapeutic interest exists for modulation of GPCR-pro-
moted signal transduction. Although most current therapies uti-
lize receptor agonists or antagonists (Rask-Andersen et al.,
2011), manipulation of GPCR signaling at steps distal to recep-
tors, such as on the level of heterotrimeric G proteins, is an
attractive alternative, particularly for diseases with complex pa-
thologies, involving multiple receptors and signaling pathways
(Smrcka, 2013). One example for small molecules interfering
with GPCR signaling at the postreceptor level are the imidazo-
pyrazine derivatives BIM-46174 and its more stable derivative
BIM-46187 (Figure 1A), each reported to dampen cellular
signaling of all four families of heterotrimeric G proteins equally,
a property coined pan-G protein inhibition (Pre´vost et al., 2006;
Ayoub et al., 2009). The pan-G protein inhibition may represent
an innovative molecular intervention to target oncogenic sig-
naling pathways.
We wanted to take advantage of the pan-G protein inhibitory
nature of BIM to study G-protein-independent signaling butnumber for the indicated simulation. (F) Simulation of GDP-Gaq (black trace),
race), BIM-dimer complex conformation I (BIM-GDP-Gaq, magenta trace). The
lix) is boxed in light blue.
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G protein subfamilies equally but rather interferes with G protein
signaling in a cellular context-dependent manner; (2) BIM may
even serve to specifically silence Gaq signaling in defined cellular
backgrounds; and (3) BIM inhibits Gabg heterotrimer function via
interference with nucleotide cycling, using a unique molecular
mechanism: precluding GTP entry into rather than GDP exit
from the nucleotide binding pocket.
Inhibition of heterotrimeric G proteins may be achieved on the
level of the abg heterotrimer or on the level of the dissociated
subunits. Of the few existing inhibitors for G protein signaling,
mechanistic details at the structural level are only available for
theGaq-selective YM-254890 (Nishimura et al., 2010). Its binding
mode, as elucidated by means of mutagenesis and structural
data, provides a plausible mechanism for inhibition of GDP
release. A similar mechanism of action has been proposed for
suramin, a polysulphonatedmolecule with a preference for inhib-
iting Gas proteins, but this molecule is of limited utility in cell-
based assays because it does not cross cell membranes due
to its strong negative charge (Smrcka, 2013; Hohenegger
et al., 1998). BIM has also been proposed to interfere with the
GDP/GTP exchange reaction, but it has not been clarified
whether BIM resembles suramin and YM in that it prevents re-
ceptor-stimulated GDP release. To address this question, we
performed radioligand binding studies under conditions that
allow assessment of nucleotide-sensitive binding states of
GPCRs. Agonist docking to GPCRs promotes an active receptor
state that engages heterotrimeric G proteins and initially triggers
GDP release from the Ga subunit (Oldham and Hamm, 2008).
Nucleotide-free G proteins, in turn, stabilize the agonist-bound
active state of GPCRs. These active-state ternary complexes
can only be observed when guanine nucleotides are absent
but are transient conformational intermediates in intact cells
where GTP and GDP are abundant (Rodbell et al., 1971; De
Lean et al., 1980; Seifert et al., 1999). Herein, we took advantage
of the formation of such active-state ternary complexes as indi-
cators for the mechanism of interference of BIM with the nucle-
otide-bound state of Ga. It is well accepted that high-affinity
agonist binding can be disrupted with high concentrations of
guanine nucleotides such as GTP because, under these condi-
tions, GDP is rapidly exchanged for GTP and the short-lived
empty pocket conformation is no longer detectable. Therefore,
agents that act like GTP, i.e., promote the uncoupling of the
activated G protein from the receptor, can be identified in radio-
ligand binding assays. Similarly, such assays are ideal for identi-
fyingmolecules that stabilize GDP-boundGa, i.e., act as guanine
nucleotide dissociation inhibitors (GDIs). Both GDIs and G-pro-
tein-uncoupling agents share the capacity to convert high-affin-
ity agonist sites into low-affinity agonist sites. BIM has been
reported to interdict function of Gabg heterotrimers (Pre´vost
et al., 2006; Ayoub et al., 2009). Inhibition of heterotrimer
signaling can only be achieved with molecules that preclude
nucleotide exchange. Because BIM does not compromise
high-affinity agonist binding, it must, consequently, permit
GDP exit and occurrence of the nucleotide-free, empty pocket
transition state of the G protein. Therefore, lack of perturbance
of high-affinity agonist binding by BIM can only be rationalized
if BIM interfered with GTP entry. Such a mechanism would be
entirely consistent with the ability of BIM to permit [3H]GDP900 Chemistry & Biology 21, 890–902, July 17, 2014 ª2014 Elsevier Ldissociation from purified Gaq proteins (Figure 7D). It also ex-
plains why BIM enhances carbachol binding to muscarinic M1
receptors in intact cells (Figure 7A), because a GTP entry
inhibitor likely prolongs the lifetime of active-state complexes.
This mechanism also rationalizes why BIM is incompetent to
completely prevent opening of the nucleotide binding pocket
of activated Gaq-bg proteins (Figure 3H) in our BRET assay. In
this experimental setup, Gaq-RLuc is coexpressed with Gg2-
GFP10 and responds with negative BRET on agonist stimulation
of a Gaq-sensitive GPCR. This BRET decrease is indicative of the
separation of the Ga-helical domain from the N terminus of Gg
and reliably reflects opening of the nucleotide binding pocket,
thereby creating the route for GDP exit and GTP entry (Gale´s
et al., 2006; Saulie`re et al., 2012). In the presence of receptor
antagonists, agonist-mediated BRET decrease can be entirely
prevented (Gale´s et al., 2006; Saulie`re et al., 2012). Inhibitors
of G protein function that act as GDIs, such as pertussis toxin,
also completely abolish agonist-mediated BRET in this experi-
mental setting (Gale´s et al., 2006). BIM, in contrast, significantly
diminishes negative BRET in response to agonist stimulation but
does not completely abolish opening of the nucleotide binding
pocket of Gaq. We infer from these BRET data (Figure 3H)—in
conjunction with our radioligand binding, docking, and MD sim-
ulations, as well as in vitro GDP dissociation studies (Figure 7)—
that BIM interdicts Gabg heterotrimer function by permitting
GDP escape but preventing GTP entry. Thus, BIM can be classi-
fied as a Gaq-specific GTP entry inhibitor that traps Gaq in the
empty pocket conformation, thereby blocking receptor-cata-
lyzed activation of the Gabg heterotrimer, a mechanism of action
not yet assigned to any other small molecule Ga inhibitor to date.
SIGNIFICANCE
Exchange of GDP for GTP on the Ga subunit is the key step
toward G protein activation and initiation of downstream
signaling. Structural, biochemical, and biophysical studies
on active and inactive conformations of heterotrimeric
G proteins have led to the recognition that Ga subunits are
endowedwith numerous clefts amenable for small molecule
targeting. However, few Ga inhibitors with activities in
cellular systems are available to date. Our study is signifi-
cant for two reasons: first, we show that two small mole-
cules, BIM-46174 and BIM-46187, previously classified as
pan-G protein inhibitors, preferably silence Gaq signaling
depending on the cellular background. Although themecha-
nistic basis underlying these disparate, cell-type-dependent
G protein inhibition profiles are not clear, BIM molecules
may be exploited as lead structures for generation of Ga
protein subfamily selective probes, which would be highly
desired to understand the contribution of G protein signaling
in physiology and disease. Our study also provides a ratio-
nale for the development of small molecule probes interro-
gating Gaq’s molecular and physiological functions and its
potential as a therapeutic target.
Second, andmore significantly, this study proves that cell-
permeable inhibitors for Ga proteins may be developed that
‘‘freeze’’ Ga in its empty pocket conformation, an intermedi-
ate conformation along the activation pathway. Such inhibi-
tors enrich the mechanistic portfolio of Ga modulators andtd All rights reserved
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with Ga to provide deeper insight into the nucleotide-free
conformation of Ga proteins. This knowledge will help to
refine our picture on the complex series of conformational
transitions from agonist binding to G protein activation—
events that underlie a host of cellular responses in hormone
and neurotransmitter signaling and, therefore, rank among
the most fundamental issues in signal transduction.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293 and COS7 cells were maintained in high glucose Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum and
1% penicillin/streptomycin mixture at 37C and 5% CO2 in a humidified atmo-
sphere. For culture of human CRTH2-HEK cells, 0.4 mg/ml G418 (InvivoGen)
was added to the medium. Stable human free fatty acid receptor 3 (FFA3)
Flp-In T-REx and human free fatty acid receptor 2 (FFA2) Flp-In T-REx cells
were cultured in DMEM supplemented with 10% fetal calf serum (FCS), 1%
penicillin/streptomycin mixture, 15 mg/ml blasticidin, and 100 mg/ml hygromy-
cin B. Expression from the Flp-In locus was induced by treatment with 1 mg/ml
doxycycline for 16–18 hr. HEK293 cells stably coexpressing the human 5-oxo-
eicosatetraenoic acid receptor (OXE-R) and the promiscuous Ga16 protein
(HEK-OXER-Ga16 cells) were maintained in DMEM supplemented with 10%
FCS, 1% penicillin/streptomycin mixture, 0.25 mg/ml hygromycin B, and
0.4 mg/ml G418.
CHO-K1 cells were cultured in Ham’s nutrient mixture F-12 GlutaMAX
supplemented with 10% (v/v) FCS and 1% penicillin/streptomycin mixture.
CHO-M1 cells were maintained in the same medium additionally supple-
mented with 0.2 mg/ml G418.
The autologous humanmelanoma cell lineMZ7-MELwas established from a
splenic melanoma metastasis in 1988. Cells were cultured in complete RPMI
1640 medium supplemented with 10% FCS (Biochrome), 2 mM L-glutamine
(GIBCO), 10 mM nonessential amino acids (GIBCO), 1 mM HEPES (GIBCO),
20 mM 2-mercaptoethanol, 100 IU/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen).
Transfection
For gene dosing experiments, the calcium phosphate DNA precipitation
method was used as described elsewhere (Kostenis et al., 2005). Assays
were performed 48 hr after transfection.
Second Messenger cAMP and IP1 Accumulation Assays
Changes of the intracellular second messengers cAMP and IP1 were quanti-
fied with the HTRF-cAMP dynamic kit and the HTRF-IP1 kit, respectively
(CisBio International), on a Mithras LB 940 reader (Berthold Technologies)
according to the manufacturer’s instructions and as described elsewhere in
detail (Schro¨der et al., 2009; Schmidt et al., 2011). If BIM or its solvent were
present during the assay, it was preincubated for 2 hr at 37C.
Crystal Violet Staining
Human melanoma cell line MZ7-MEL was seeded into 96-well plates (2 3
104 per well) in complete RPMI medium. BIM was added to the cells in
various concentrations (0.1, 0.3, 1, 3. and 10 mM) along with its vehicle.
After 72 hr, cells were washed with PBS and fixed with 4% paraformalde-
hyde for 5 min. Afterward, cells were stained with 0.05% crystal violet
dye for 30 min, rinsed twice with tap water, and thoroughly dried. Staining
intensity was measured using the Li-Cor Odysee SA imaging system.
Values are expressed as percentage staining intensity ± SEM relative to
control.
Colorimetric XTT Assay
Human melanoma cell line MZ7-MEL was seeded into 96-well plates (2 3 104
per well). Solvent control, BIM (0.1, 1, 10 and 100 mM), or the cell cycle inhibitor
aphidicolin (1 mg/ml) were added in various concentrations to the cells. After
72 hr, cell viability was measured using the XTT-based Cell Proliferation Kit IIChemistry & Biology 21,(Roche) according to the manufacturer’s protocols. Absorption wasmeasured
at 405 nm using an ELISA-Reader. Results are expressed as percentagemeta-
bolic activity ± SEM relative to control.
Western Blot
Protein lysates were prepared from native HEK293 andMZ7-MEL cells as well
as HEK293 cells transfected with different amounts of hemagglutinin (HA)-
tagged Gaq protein. Samples (10 or 20 mg of protein) were dissolved in
SDS-PAGE sample buffer, heated at 70C for 10 min, fractionated on 10%
acrylamide gels, and electrically transferred to nitrocellulose membranes.
Membranes were blocked with Roti Block (Carl Roth) and then incubated in
primary antibody solution: anti-HA (#11583816001, Roche); anti-b-tubulin
(#3708-100, BioVision); anti-Gaq/11 (sc-392), anti-Gas (sc-823), and anti-Gai3
(sc-262, all from Santa Cruz Biotechnology). Bound antibodies were detected
with an anti-rabbit horseradish-peroxidase-conjugated secondary antibody
(ABIN 102010, antibodies-online), visualized by ECL Prime Western blotting
reagent (RPN2232, Amersham), and quantified by densitometry (GelScan
V6.0 Software).
Single Cell [Ca2+]i Imaging
MZ7-MEL tumor cells were incubated for 2 hr with BIM (100 mM) or its solvent
DMSO (1:500) in RPMI medium (20% FCS) at 37C, and mobilization of [Ca2+]i
was monitored as outlined in detail in Supplemental Experimental Procedures.
BRET
G protein activation was quantified in HEK293 cells transiently transfected to
express GPR55, Ga13-106RLuc8 (human muscarinic receptor M3 and Gaq-
97RLuc8 for Gaq pathway), Gg2-GFP
10, and unlabeled Gb1. Assays were per-
formed 48 hr after transfection. Cells were detached and resuspended in
Hank’s balanced salt solution with 20 mM HEPES at a density of 1.06 3 106
cells per ml. A volume of 170 ml cell suspension was seeded in 96-well micro-
plates and incubated with BIM or buffer for 2 hr. After agonist addition, cells
were incubated for 2 min (1 min for carbachol). G protein activation was
measured after the addition of RLuc substrate DeepBlueC coelenterazine
(Gold Biotechnology). To detect BRET, light emission at 400 and 515 nm
was measured sequentially using a Mithras LB 940 instrument. The BRET
signal (milliBRET ratio) was determined by calculating the ratio of the light
emitted by the fluorescence acceptor GFP10 (515 nm) and the light emitted
by Rluc (400 nm).
Other Methods
For synthesis of BIM-monomer and -dimer, remaining experimental proce-
dures, and a more detailed description of the aforementioned procedures,
see the Supplemental Information.
Data Analysis
Results are expressed asmean values ± SEM andwere analyzed usingGraph-
Pad Prism 5.04 (Graph Pad). Half maximal effective concentration (EC50)
values were determined by nonlinear regression, and comparison between
two experimental groups was based on a two-tailed Student t test. The
p values were considered as significant (*p < 0.05), very significant (**p <
0.01), and extremely significant (***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.06.003.
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